Novartis was already riding a wave of momentum with Kisqali, and now it has a new FDA nod to break into the early breast ...

The FDA on Tuesday firmed up its position that in some limited circumstances, clinical trial data may be obtained from ...

Merck and Daiichi Sankyo have passed a Phase 3 with the lead antibody-drug conjugate from the megadeal they disclosed at last ...

In early 2023, the founder of the psychedelic medicine company Lykos Therapeutics met with a potential investor for dinner, ...

Supplies of Coherus Biosciences' biosimilar version of the white blood cell-stimulating drug Neulasta will be “substantially ...

Cigna, the owner of one of the top pharmacy benefit managers, is suing the Federal Trade Commission and Commissioner Lina ...

One of this weekend’s sleeper data presentations at Europe’s biggest oncology conference puts Pfizer in a leading position in ...

A promising new approach that could slow, stop or prevent nerves from dying may get its first test in patients next year.

Plus, news about Vigil Neuroscience, AC Immune and Athira Pharma: Capricor Therapeutics, Nippon Shinyaku expand commercial pact into Europe: The new deal builds off an existing partnership for a ...

More than 33,000 oncologists, medical researchers, biopharma leaders and other delegates attended Europe’s largest cancer meeting over the past few days in Spain, with more than 181 countries ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get ...